Katerina Mardilovich
About Katerina Mardilovich
Katerina Mardilovich is a Principal Scientist in T Cell Process Development at Adaptimmune US, where she has worked since 2020. She holds a PhD from the University of Massachusetts Medical School and has contributed to significant research in T-cell therapies and signaling pathways.
Work at Adaptimmune
Katerina Mardilovich serves as a Principal Scientist in T Cell Process Development at Adaptimmune US. She has held this position since 2020, contributing to advancements in T-cell therapies. Her work focuses on the development and optimization of processes related to T-cell expansion and functionality, particularly in the context of targeted therapies.
Education and Expertise
Katerina Mardilovich earned her Doctor of Philosophy degree from the University of Massachusetts Medical School, where she studied from 2004 to 2011. Prior to that, she completed her Bachelor of Science degree at Worcester Polytechnic Institute from 2002 to 2004. Additionally, she attended the International Sakharov Environmental University from 2000 to 2002, further enhancing her academic background.
Research Contributions
Mardilovich has contributed to significant research in the field of immunology, particularly focusing on the inhibition of AKT signaling during T-cell expansion. Her work has implications for improving T-cell therapies, including those targeting specific antigens such as MAGE-A4. She has also been involved in enhancing the functional potential of SPEAR T-Cells.
Presentations and Conferences
Katerina Mardilovich has presented her research findings at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. Her presentations contribute to the ongoing dialogue in the field of cancer immunotherapy and showcase her expertise in T-cell development and therapeutic strategies.